Athira Pharma, Inc. Common Stock (ATHA)
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Athira Pharma, Inc. Common Stock (ATHA) was listed on Nasdaq from September 18, 2020 and stopped trading under the symbol ATHA on January 12, 2026.
- Listed On
- Nasdaq
- Listed Since
- September 18, 2020
- Stopped Trading
- January 12, 2026
- Employees
- 26
About Athira Pharma, Inc. Common Stock
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
Institutional ownership
In 13F filings for the quarter ended December 31, 2025, 1 institution reported holding ATHA, with 1,014 shares worth $452 in aggregate. The largest reported holder was Barclays, with 1,014 shares worth $452. Of the 1 largest holders listed below, 1 opened a new position in ATHA during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Barclays | 1,014 | $452 | New position |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is ATHA?
Athira Pharma, Inc. Common Stock (ATHA) was listed on Nasdaq from September 18, 2020 and stopped trading under the symbol ATHA on January 12, 2026.
Who are the largest institutional holders of ATHA?
In 13F filings for the quarter ended December 31, 2025, the largest reported holders of ATHA were Barclays.
How many institutions own ATHA?
1 institution reported a position in ATHA for the quarter ended December 31, 2025, worth $452 in total.
Did institutions buy or sell ATHA last quarter?
Of the 1 largest reported holders, 1 opened a new position in ATHA during the quarter. Every reported holder and its change is on the SentiSense ownership page for ATHA.
Every reported institutional holder, plus insider and congressional trades in ATHA, on SentiSense.